We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Telmisartan (Micardis) — angiotensin-receptor blocker (ARB) + partial PPARγ agonist
An angiotensin-receptor blocker (Micardis) that is unusual among RAS drugs for also being a partial PPARγ agonist — the receptor that glitazone diabetes drugs target. That dual action gives it a metabolic edge: across head-to-head RCTs and a meta-analysis it improves insulin sensitivity, glucose, and lipids more than other ARBs, which is why it features in geroscience discussions. But it is an approved blood-pressure drug whose proven outcomes are cardiovascular, not a demonstrated lifespan/healthspan benefit — and its own pivotal trials show no superiority over ramipril (ONTARGET) and no recurrent-stroke reduction (PRoFESS). A prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Telmisartan is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Telmisartan studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2008–2026 with a typical study size of 235 participants.
Based on 52 studies · 10 meta-analyses · 38 RCTs · 93,554 total participants
Confidence
High confidenceBy outcome
Telmisartan is the one ARB that is also a partial PPARγ agonist — head-to-head RCTs and a meta-analysis show it improves insulin sensitivity, glucose, and lipids more than other ARBs, and mechanistic RCTs confirm it engages PPARγ target genes in humans, giving it a real metabolic/geroscience angle. But its proven outcomes are cardiovascular (ONTARGET: non-inferior to ramipril), the metabolic endpoints are surrogate markers not lifespan, ONTARGET showed no superiority and the combination arm increased renal harm, and PRoFESS was a clean negative stroke trial — so the metabolic-longevity use stays emerging.
43 rigorous studies
38 randomized trials · 5 meta-analyses · 2 systematic reviews
Our evidence rating for Telmisartan is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
16 trials ongoing or recruiting · 278 completed on ClinicalTrials.gov
61 of the completed trials have posted results
Registered trials show research momentum for Telmisartan, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Telmisartan is an angiotensin II type-1 (AT1) receptor blocker (ARB) marketed as Micardis — a long-acting, once-daily antihypertensive.
What sets it apart from the rest of its class, and from the other renin-angiotensin (RAS) drugs in this collection (losartan, captopril), is a second pharmacology: telmisartan is a partial agonist of peroxisome proliferator-activated receptor-gamma (PPARγ), the nuclear receptor that the glitazone (thiazolidinedione) diabetes drugs activate.
As a *selective* PPARγ modulator it engages the receptor enough to favorably shift glucose and lipid metabolism without the full-agonist downsides of fluid retention and weight gain (Kurtz 2008). That dual AT1-blockade-plus-PPARγ profile is the source of its metabolic and geroscience interest.
The human evidence for the metabolic angle is real but modest: head-to-head RCTs against other ARBs show telmisartan improves insulin sensitivity, fasting glucose, and lipids more than comparators, a meta-analysis pooling those trials concludes telmisartan improves insulin resistance relative to other ARBs (Wang 2018), and mechanistic RCTs in metabolic-syndrome patients show high-dose telmisartan induces monocytic PPARγ target genes (Bähr 2011) — direct in-human confirmation that the PPARγ pathway is engaged.
The honest distinction this collection insists on: the PPARγ/metabolic-syndrome story is mechanistically genuine and is discussed in the geroscience literature (PPARγ and RAS modulation are both candidate metabolic-aging levers), but it has NOT been shown to extend lifespan or healthspan — the endpoints in the human trials are surrogate metabolic markers, not aging or mortality.
On the cardiovascular side the evidence is solid: ONTARGET (Yusuf 2008) established telmisartan as non-inferior to the gold-standard ACE inhibitor ramipril for the composite of cardiovascular death, MI, stroke, and heart-failure hospitalization in high-vascular-risk patients — but it showed no *superiority*, and the combination arm (ARB + ACE inhibitor together) caused MORE harm, with worse renal outcomes including more dialysis/creatinine-doubling and hypotension.
TRANSCEND (Yusuf 2008) extended telmisartan to patients intolerant of ACE inhibitors.
The best counter-evidence is PRoFESS (Yusuf 2008): in 20,000+ patients started on telmisartan soon after an ischemic stroke, it did NOT significantly reduce recurrent stroke — a large, clean negative trial that caps the cerebrovascular claim.
Telmisartan is generally well tolerated (ARB class — less cough than ACE inhibitors); class effects are dizziness/hypotension, hyperkalemia, and a contraindication in pregnancy.
It is a prescription cardiovascular drug; using it off-label for metabolic/longevity ends is increasingly discussed, but the longevity benefit specifically is unproven.
The score reflects a genuinely distinctive, in-human-confirmed PPARγ/metabolic mechanism plus solid cardiovascular outcome data, against unproven human longevity, no superiority over ramipril, and a clear negative stroke trial.
Telmisartan blocks the angiotensin II type-1 (AT1) receptor, lowering angiotensin II signaling — the renin-angiotensin axis that, beyond blood pressure, drives inflammation, oxidative stress, fibrosis, and senescence.
Uniquely among ARBs, telmisartan partially activates PPARγ — the nuclear receptor glitazone diabetes drugs target — as a selective modulator, improving glucose/lipid metabolism without the full-agonist fluid retention and weight gain (Kurtz 2008).
Via PPARγ engagement, telmisartan improves insulin sensitivity and lipids more than other ARBs in head-to-head trials, and induces PPARγ target genes (CD36/CD163) in human monocytes (Bähr 2011).
How Telmisartan works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated — ARBs cause fetal renal and developmental harm.
Monitor kidney function and potassium closely; never add an ACE inhibitor.
Caution — hypotension risk; correct dehydration first and start low.
Combining an ARB with an ACE inhibitor increased renal failure, hyperkalemia, and hypotension in ONTARGET without added benefit — avoid.
Additive hyperkalemia risk — can be dangerous.
Reduce ARB effect and can worsen renal function (the 'triple whammy' with diuretics).
ARBs raise lithium levels and toxicity risk.
Tip: Most likely with dehydration or alongside diuretics; start low and rise slowly.
Tip: Monitor potassium; avoid potassium supplements/salt substitutes, especially in renal impairment.
Tip: Much rarer than with ACE inhibitors; stop immediately and seek care.
Telmisartan has an evidence score of 4.3/10 — emerging evidence based on 25 indexed studies, including 1 meta-analysis. An angiotensin-receptor blocker (Micardis) that is unusual among RAS drugs for also being a partial PPARγ agonist — the receptor that glitazone diabetes drugs target. That dual action gives it a metabolic edge: across head-to-head RCTs and a meta-analysis it improves insulin sensitivity, glucose, and lipids more than other ARBs, which is why it features in geroscience discussions. But it is an approved blood-pressure drug whose proven outcomes are cardiovascular, not a demonstrated lifespan/healthspan benefit — and its own pivotal trials show no superiority over ramipril (ONTARGET) and no recurrent-stroke reduction (PRoFESS). A prescription drug, not a supplement. Representative study: PMID 29557807.
The commonly studied dose of Telmisartan is Approved antihypertensive dosing is 20–80 mg once daily; the metabolic/PPARγ effects are most evident at the higher 80 mg (and study) doses, under a clinician. Not an approved metabolic or longevity regimen; blood pressure, kidney function, and potassium should be monitored.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Telmisartan is in the morning. It can be taken on an empty stomach. Long-acting; taken once daily, with or without food.
Telmisartan should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are dizziness / hypotension, hyperkalemia, angioedema. Use caution if any of these apply to you: Pregnancy (fetal harm); Bilateral renal artery stenosis; Hyperkalemia.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Canagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Invokana) that lowers glucose by excreting it in urine. It extended lifespan in male mice in the NIA aging program, and the SGLT2 class has strong proven cardiovascular, kidney, and heart-failure benefits in humans. Longevity benefit itself is unproven; carries genital-infection and (rarely) ketoacidosis risks. Prescription drug, not a supplement.
Empagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Jardiance) with the strongest human outcome evidence of its class — it cuts cardiovascular death, heart-failure hospitalization, and kidney-disease progression even in non-diabetics. The most widely used SGLT2 for off-label 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Dapagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Farxiga/Forxiga) with broad, robust human outcome evidence — it cuts heart-failure hospitalization and cardiovascular death across the ejection-fraction spectrum and slows kidney-disease progression, including in non-diabetics. The sibling of empagliflozin, used off-label for 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 52 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research